YOLFTbeta
Shenyang Xingqi Pharmaceutical Co Ltd

Shenyang Xingqi Pharmaceutical Co Ltd

300573 · SHE · Healthcare / Medical Instruments & Supplies

33.57CNY-0.71 (-2.07%)

Price History

Full chart

Market Stats

Previous Close34.28
Open34.22
Day Range33.50 – 34.30
52-Week Range34.82 – 57.30
Volume4.81M
Market Cap12.93B
P/E (TTM)16.48
Forward P/E0.00
EPS2.21
Dividend Yield3.57%
Beta0.08
50-Day Avg39.19
200-Day Avg44.16

About

Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, dry eye treatment medicines, mydriatics and cycloplegia drugs, miotics and anti-glaucoma drugs, and intraoperative intraocular irrigation fluids. It also engages in technology development, technical advice, eye hospital, and research and experimental development activities. Shenyang Xingqi Pharmaceutical Co.,Ltd. was founded in 1977 and is based in Shenyang, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMs. E. Gao
  • Employees2.40K
  • HeadquartersBuilding B, Enterprise Plaza, Shenyang, China, 110016, China
  • Websitehttps://www.sinqi.com

Leadership

  • Ms. E. GaoMD, GM & Non-Independent Director · b. 1974
  • Mr. Shaoyao ZhangDeputy Chairman, Deputy GM & Secretary of the Board · b. 1970
  • Ms. Yanan ChengDeputy GM, Financial Director, CFO & Non-Independent Director · b. 1974
  • Mr. Chunhua LiDirector of the Administrative Management Department & Director · b. 1977
  • Mr. Qiang YangHead of R&D Center, Deputy GM & Director · b. 1984
  • Xie MinHead of the Accounting Department & Accounting Supervisor
  • Ms. Fei JiHuman Resources Specialist & Employee Representative Supervisor · b. 1993

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue190.54M212.33M218.63M254.65M287.44M339.10M360.01M431.20M542.43M688.68M1.03B1.25B1.47B1.94B2.47B
Growth (%)-+11.44%+2.97%+16.48%+12.88%+17.97%+6.17%+19.78%+25.80%+26.96%+49.26%+21.59%+17.42%+32.42%+27.24%
Cost of Revenue20.60M25.74M30.12M65.81M86.78M85.04M95.27M121.50M147.18M187.87M229.01M270.08M340.36M424.53M465.96M
Gross Profit169.94M186.59M188.51M188.85M200.66M254.06M264.73M309.71M395.26M500.81M798.91M979.78M1.13B1.52B2.01B
Gross Margin89.19%87.88%86.22%74.16%69.81%74.92%73.54%71.82%72.87%72.72%77.72%78.39%76.81%78.16%81.16%
Operating Expense129.02M137.47M135.94M170.78M179.09M195.98M218.59M298.18M357.57M395.07M550.51M729.68M850.70M1.09B1.16B
Operating Income40.92M49.12M52.57M18.07M21.58M58.08M46.15M11.52M37.69M105.74M248.40M250.10M276.52M424.75M843.77M
Operating Margin21.48%23.14%24.05%7.10%7.51%17.13%12.82%2.67%6.95%15.35%24.17%20.01%18.84%21.86%34.12%
EBITDA43.13M53.27M63.45M62.17M71.35M95.82M81.69M46.71M78.05M157.61M297.55M297.23M340.30M499.83M917.40M
EBITDA Margin22.64%25.09%29.02%24.41%24.82%28.26%22.69%10.83%14.39%22.89%28.95%23.78%23.19%25.72%37.10%
Net Income35.64M43.70M46.10M31.01M21.98M54.28M39.44M13.66M35.89M87.98M194.70M211.68M240.04M338.06M695.86M
Net Income Margin18.70%20.58%21.08%12.18%7.65%16.01%10.95%3.17%6.62%12.77%18.94%16.94%16.36%17.40%28.14%
R&D8.75M9.72M11.19M10.27M15.95M19.59M34.28M40.97M53.97M63.19M88.45M145.61M167.30M226.07M225.91M
R&D as % of Total Revenue4.59%4.58%5.12%4.03%5.55%5.78%9.52%9.50%9.95%9.18%8.60%11.65%11.40%11.63%9.14%
Interest Expense1.48M33.32K793.90K11.10M12.06M7.43M3.10M3.19M4.65M6.44M6.84M1.75M1.89M6.52M4.44M
Interest Expense % of Total Revenue0.77%0.02%0.36%4.36%4.20%2.19%0.86%0.74%0.86%0.94%0.67%0.14%0.13%0.34%0.18%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets267.88M418.02M567.21M670.90M650.94M721.41M676.48M708.47M852.37M1.00B1.69B1.78B2.02B2.13B2.54B
Total Liabilities20.88M127.32M230.41M303.09M261.15M200.47M123.09M153.89M277.46M309.42M342.35M230.63M333.92M534.48M560.93M
Total Equity247.00M290.70M336.80M367.81M389.79M520.95M550.38M545.53M568.51M682.19M1.34B1.55B1.69B1.59B1.98B
Cash96.56M98.99M52.02M20.90M10.83M90.61M22.29M28.37M49.96M37.22M686.36M515.45M480.42M370.12M393.71M
Total Debt-60.00M125.70M126.00M100.00M80.00M50.00M50.00M90.00M109.90M107.10M6.69M72.28M209.03M-
Net Debt-96.56M-38.99M73.68M105.10M89.17M-10.61M27.71M21.63M40.04M72.68M-579.26M-508.76M-408.14M-161.09M-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow24.54M41.96M8.40M13.00M21.43M28.12M32.70M44.01M74.08M122.16M306.96M286.26M317.57M416.98M753.39M
Investing Cash Flow-39.85M-98.25M-120.21M-62.83M17.10M8.14M-31.38M-45.09M-69.94M-108.15M-202.01M-299.15M-261.94M-215.67M-
Financing Cash Flow67.21M48.73M48.16M45.18M-48.29M43.49M-69.68M7.23M5.79M-15.08M538.12M-158.42M-84.17M-318.79M-
Capital Expenditure42.06M103.25M132.98M81.79M4.69M3.62M29.29M45.29M69.98M108.15M95.06M299.23M261.96M198.71M270.53M
Free Cash Flow-17.52M-61.29M-124.58M-68.79M16.75M24.50M3.41M-1.28M4.11M14.01M211.90M-12.96M55.61M218.27M482.86M
Dividends Paid23.53M-3.67M10.53M10.59M6.56M13.01M22.88M20.00M10.30M41.17M79.28M177.11M466.57M351.08M
FCF to OCF-71.38%-146.06%-1483.39%-529.26%78.13%87.13%10.42%-2.90%5.54%11.47%69.03%-4.53%17.51%52.35%64.09%
Dividend Paid to FCF-134.34%--2.95%-15.31%63.27%26.76%381.76%-1790.18%487.15%73.56%19.43%-611.60%318.51%213.76%72.71%

Earnings

Report DateDec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Apr 20, 2020Aug 27, 2020Oct 29, 2020Dec 31, 2020Apr 27, 2021Sep 13, 2021Oct 27, 2021Dec 31, 2021Apr 19, 2022Aug 28, 2022Oct 26, 2022Dec 31, 2022Apr 26, 2023Aug 28, 2023Oct 23, 2023Jan 5, 2024Apr 18, 2024Jun 30, 2024Oct 28, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------
EPS Actual0.030.030.060.04-0.01-0.010.000.050.000.000.010.070.02-0.130.320.480.100.400.570.900.110.480.530.930.030.100.770.760.460.280.380.700.130.830.530.740.270.580.63
Surprise---------------------------------------
Timing-----------------After-hoursAfter-hoursPre-market-Pre-marketAfter-hoursPre-market-Pre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-market-Pre-market-----

Key Statistics & Ratios

Market Cap12.93B
Enterprise Value12.61B
Trailing P/E16.48
Forward P/E0.00
Price / Sales4.77
Price / Book6.02
EPS2.21
Book Value6.05
Revenue (TTM)2.71B
Gross Profit (TTM)2.22B
EBITDA1.01B
Profit Margin29.19%
Operating Margin35.32%
Return on Equity40.37%
Return on Assets22.30%
Shares Outstanding354.92M
Shares Float245.56M
Beta0.08
Dividend Yield3.57%
Dividend Rate1.30
Payout Ratio58.73%

Dividends

20261×
1.00May 22, 2026
20252×
0.48Sep 24, 20250.49May 22, 2025
20242×
0.25Oct 16, 20241.48May 22, 2024
20232×
0.35Sep 22, 20230.25May 22, 2023
20222×
0.13Sep 23, 20220.10May 20, 2022
20212×
0.06Sep 29, 20210.06May 21, 2021
20201×
0.03May 21, 2020
20191×
0.06Jun 11, 2019
20181×
0.06Jun 1, 2018
20171×
0.03Jun 21, 2017

Stock Splits

  • May 22, 20261.45:1
  • May 22, 20251.4:1
  • May 22, 20241.4:1
  • Sep 22, 20231.4:1